Human herpesvirus-6 and cytomegalovirus DNA in liver donor biopsies and their correlation with HLA matches and acute cellular rejection

Guardia, A.C.; Stucchi, Raquel Silveira Bello; Milan, Arlete; Costa, Sandra Cecı́lia Botelho; Boin, I.F.S.F.

doi:10.1016/j.bjid.2013.07.007

Cited by 4 publications

(5 citation statements)

References 19 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 A study of 59 liver transplant patients found that HLA-DR15 was associated with HHV-6 positivity in donor biopsies and that patients with HLA-DR15 in liver donor biopsies developed more rejection after liver transplantation. 60 In a study of 33 paediatric liver transplant recipients, HHV-6 was detected in 3 (9.1%) patients and HHV-6 infection was associated with concurrent episodes of moderate to severe acute graft rejection in two of the three children. 15 Finally, a prospective study of 548 liver transplant recipients reported a higher rate of allograft rejection in patients with ciHHV-6 (71.4%) compared to patients with low level HHV-6…”

Section: Allograft Rejection and Survivalmentioning

confidence: 95%

“…However, when 41 cases of rejection post day 30 were analysed, HHV‐6 viral load was an independent predictor of rejection (odds ratio 2.27, 95% CI 1.09‐4.77; P =.029) . A study of 59 liver transplant patients found that HLA‐DR15 was associated with HHV‐6 positivity in donor biopsies and that patients with HLA‐DR15 in liver donor biopsies developed more rejection after liver transplantation . In a study of 33 paediatric liver transplant recipients, HHV‐6 was detected in 3 (9.1%) patients and HHV‐6 infection was associated with concurrent episodes of moderate to severe acute graft rejection in two of the three children .…”

Section: Conditions Associated With Hhv‐6 In Liver Transplant Patientsmentioning

confidence: 99%

See 1 more Smart Citation

HHV‐6 in liver transplantation: A literature review

Phan

Lautenschlager

Razonable

et al. 2017

Liver International

View full text Add to dashboard Cite

Human herpesvirus 6 (HHV-6A and HHV-6B) can cause primary infection or reactivate from latency in liver transplant recipients, which can result in a variety of clinical syndromes, including fever, hepatitis, encephalitis and higher rates of graft dysfunction as well as indirect effects including increased risks of mortality, CMV disease, hepatitis C progression and greater fibrosis scores. Although HHV-6 infection is currently diagnosed by quantifying viral DNA in plasma or blood, biopsy to demonstrate

show abstract

Section: Allograft Rejection and Survivalmentioning

confidence: 95%

Section: Conditions Associated With Hhv‐6 In Liver Transplant Patientsmentioning

confidence: 99%

HHV‐6 in liver transplantation: A literature review

Phan

Lautenschlager

Razonable

et al. 2017

Liver International

View full text Add to dashboard Cite

show abstract

“…HHV-6 infection associated with higher incidence of opportunistic infections, invasive fungal infections and mycobacterial disease 158 , 164 . HLA-DR15 positivity in donor liver biopsy predisposed the graft to HHV-6 infections and subsequent rejection 165 . HHV-6 is highly cell bound and the rates of PCR positivity are less in plasma (33%) and whole blood(19%).…”

Section: Human Herpes Virusmentioning

confidence: 99%

Post liver transplant recurrent and de novo viral infections

Jothimani

Venugopal

Vij

et al. 2020

Best Practice & Research Clinical Gastroenterology

View full text Add to dashboard Cite

Survival following liver transplantation has changed dramatically owing to improvement in surgical techniques, peri-operative care and optimal immunosuppressive therapy. Post-Liver transplant (LT) de novo or recurrent viral infection continues to cause major allograft dysfunction, leading to poor graft and patient survival in untreated patients. Availability of highly effective antiviral drugs has significantly improved post-LT survival. Patients transplanted for chronic hepatitis B infection should receive life-long nucleos(t)ide analogues, with or without HBIg for effective viral control. Patients with chronic hepatitis C should be commenced on directly acting antiviral (DAA) drugs prior to transplantation. DAA therapy for post-LT recurrent hepatitis C infection is associated with close to 100% sustained virological response (SVR), irrespective of genotype. De novo chronic Hepatitis E infection is an increasingly recognised cause of allograft dysfunction in LT recipients. Untreated chronic HEV infection of the graft may lead to liver fibrosis and allograft failure. Similarly, CMV and EBV can reactivate leading to systemic illness following liver transplantation. With COVID-19 pandemic, post-transplant patients are at risk of SARS-Co-V2 infection. Majority of the LT recipients require hospitalisation, and the mortality in this population is around 20%. Early recognition of allograft dysfunction and identification of viral aetiology is essential in the management of post-LT de novo or recurrent infections. Optimising immunosuppression is an important step in reducing the severity of allograft damage in the treatment of post-transplant viral infections. Viral clearance or control can be achieved by early initiation of high potency antiviral therapy.

show abstract

“…The coinfection of HCMV and HHV-6 often results in severe morbidity in SOTs [136,137]. Prospective studies are required to investigate the influence of other herpesvirus on reactivation of HCMV in patients with clinical complications.…”

Section: Pathophysiology Relevance Of Hcmv Latencymentioning

confidence: 99%

Epigenetic Regulation of Human Cytomegalovirus Latency: an Update

Kumar

Herbein

2014

Epigenomics

View full text Add to dashboard Cite

Human cytomegalovirus (HCMV) is a ubiquitous virus which infects 50-90% of the population worldwide. In immunocompetent hosts, HCMV either remains unnoticed or causes mild symptoms. Upon primary infection it establishes latent infection in a few cells. However, in certain situations where immunity is either immature or compromised, HCMV may reactivate and cause mortality and morbidity. Therefore, it is utmost important to understand how HCMV establishes latent infection and associated mechanisms responsible for its reactivation. Several mechanisms are involved in the regulation of latency including chromatin remodeling by an array of enzymes and microRNAs. Here we will describe the epigenetic regulation of HCMV latency. Further we will discuss the unique HCMV latency signature and patho-physiological relevance of latent HCMV infection.

show abstract

Human herpesvirus-6 and cytomegalovirus DNA in liver donor biopsies and their correlation with HLA matches and acute cellular rejection

Abstract: HHV-6 DNA was prevalent in liver donors studied as well as HLA-DR 15. These findings suggest that patients with HLA-DR 15 in liver donor biopsies develop more rejection after liver transplantation.

Cited by 4 publications

References 19 publications

HHV‐6 in liver transplantation: A literature review

HHV‐6 in liver transplantation: A literature review

Post liver transplant recurrent and de novo viral infections

Epigenetic Regulation of Human Cytomegalovirus Latency: an Update

Contact Info

Product

Resources

About